banda transcan 2 2016ul

Title: Employing NGS technology for improved, non-invasive early detection, staging and prediction of progression in lymphoma patients

Project Coordinator:
Paolo GHIA (Italy) IRCCS Ospedale San Raffaele, Milan

Project Partners:
Anastasia HADZIDIMITRIOU (Greece) Centre for Research and Technology Hellas, Thessaloniki
Anton W. LANGERAK (The Netherlands) Erasmus MC, Rotterdam
Frederic DAVI (France) Université Pierre et Marie Curie & Hôpital Pitié-Salpêtrière, Paris
Christiane POTT (Germany) University Hospital Schleswig. Holstein Campus Kiel, Kiel
Dimitris VASSILIADIS (Greece) EXODUS SA, Athens
Roel C. H. VERMEULEN (The Netherlands), Utrecht University, Utrecht

Project Abstract:
Background, rationale: B-cell non-Hodgkin lymphomas (B-NHL) are more frequent in healthy individuals with a family history of lymphoma and in immunocompromised patients. B-NHL display widely heterogeneous clinical behavior: aggressive lymphomas need immediate therapy, though a fraction of cases cannot be effectively treated due to late recognition and/or incorrect staging at diagnosis because of limited sensitivity of the current diagnostic procedures; in contrast, indolent lymphomas do not necessarily need immediate treatment but are bound to long-term repetitive follow-ups (with inevitable psychological and economic burden for many patients who will need none or only late therapies) because of a lack of validated biomarkers able to predict clinical progression requiring treatment. The same uncertainity and burden apply to individuals carrying pre-lymphomatous conditions with inconclusive risk of progression to overt lymphoma.
Hypothesis: The gold standard source of material to establish the diagnosis and define the stage (including pre-malignant situations) of most B-NHL is tissue biopsy, an invasive procedure, being physically damaging, painful and even potentially dangerous. This proposal is based on the hypothesis that the use of minimally invasive procedures such as liquid biopsies from peripheral blood assessed by high-throughput analysis of molecular biomarkers will allow to (i) detect early disease through screening populations at risk; (ii) risk-stratify individuals carrying pre-lymphomatous conditions for progression to overt lymphoma; (iii) refine molecular diagnosis and staging in B-NHL.
Aims: 1. To detect early disease through screening procedures in populations at risk. 2. To risk-stratify individuals carrying pre-lymphomatous conditions or indolent lymphomas for progression to overt disease. 3. To refine diagnosis and staging in B-NHL.
Methods: We will utilize Next Generation Sequencing (NGS) in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) obtained from peripheral blood samples (a.k.a. liquid biopsy), and perform immunogenetic analysis of the unique IGHV-IGHD-IGHJ monoclonal rearrangements and analysis of recurrently mutated genes in B-NHL/CLL.
Expected results: We expect to achieve validated and implemented procedural and analytical pipelines for NGS profiling of B-NHL/CLL-specific biomarkers in liquid biopsies. We will also define validated and implemented bioinformatics workflows and tools for widespread use in a diagnostic setting.
Potential impact: The successful completion of the NOVEL proposal will allow to achieve accurate outcome prediction and improved survival through risk stratification of individuals carrying pre lymphomatous or indolent conditions for evolution to overt lymphoma and refined molecular diagnosis/staging in the aggressive forms. Potentially, the procedural and analytical pipelines could be utilized also for the management of other neoplastic conditions.
Potential impact: The successful completion of the NOVEL proposal will allow to achieve accurate outcome prediction and improved survival through risk stratification of individuals carrying pre-lymphomatous or indolent conditions for evolution to overt lymphoma and refined molecular diagnosis/staging in the aggressive forms. Potentially, the procedural and analytical pipelines could be utilized also for the management of other neoplastic conditions.

 

 

(Project funded under JTC 2016)


TRANSCAN News

 TRANSCAN-3 news on:
twitter logoinkedin social media logo

TRANSCAN-3   JOINT TRANSNATIONAL CALL 2022 on:
 "Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy"  

is open for submission

Please visit the TRANSCAN-3 website at
https://transcan.eu/funding/calls/joint-call-jtc-2022-.kl


Other news:

The Digital Institute for Cancer Outcomes Research (DIGICORE),  is delighted to announce an innovative new training programme for early career researchers in oncology: IDEAL4RWE.
 Please register for an introductory webinar on the19th April 2022(https://lnkd.in/ez7y4kWU).
Brochure for more details: https://tinyurl.com/y7aurdtk


 The first TRANSCAN-3 call (JTC 2021) on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"
is closed for submission

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

The new ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

Newsletters

The TRANSCAN-3 newsletters are published at: https://www.transcan.eu/

SUBSCRIBE to the newsletters
You can unsubscribe at any moment by clicking on the subscription preferences link at the bottom of a received newsletter


All the TRANSCAN-2 newsletters:

Newsletter 10, Sept.2020
Newsletter 9, Dec.2019

Newsletter 8, May 2019
Newsletter 7, Oct.2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, Dec. 2017
Newsletter 3, Sept. 2017
Newsletter 2, April 2017
Newsletter 1, Dec. 2016

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 9 guests and no members online